Document Detail


Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.
MedLine Citation:
PMID:  21175705     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
WHAT IS KNOWN AND OBJECTIVE: Interferon-alfa-based therapy is effective in the treatment of Hepatitis C. However, some patients fail to respond and others relapse, after initially responding. Our objective was to assess the efficacy, safety and predictive factors for sustained virological response (SVR) to peginterferon plus ribavirin in chronic hepatitis C patients who failed to interferon-alfa (IFNα)-based therapy.
METHODS: Seventy-five consecutive patients who failed to IFNα-based therapy were retreated with peginterferon plus ribavirin. Of these patients, 85% were infected by genotype 1. The primary endpoint was SVR.
RESULTS AND DISCUSSION: Of 75 non-responder (n = 54) or relapser patients (n = 21), 50 were previously treated with IFNα-monotherapy and 25 with IFNα plus ribavirin. Global SVR rate was 41.3%: for patients re-treated with IFNα the response was 48% whilst for those retreated with IFNα plus ribavirin, it was 28%. For previous non-responders the SVR rate was 37% and for relapsers it was 52.4%.
WHAT IS NEW AND CONCLUSION: Retreatment with peginterferon plus ribavirin is an effective option for some chronic hepatitis C non-responder or relapser patients. Higher SVR rate was achieved in relapsers and in those patients who received IFNα monotherapy previously.
Authors:
M Trapero-Marugán; J Mendoza; J A Moreno Monteagudo; M Chaparro; L García-Buey; L González-Moreno; M J Borque; R Moreno-Otero
Related Documents :
17845935 - Chylothoraces after lung transplantation for lymphangioleiomyomatosis: review of the li...
21221915 - End of life care in advanced heart failure.
9619595 - Pulmonary mycotoxicosis: a clinicopathologic study of three cases.
21075605 - Risk factors and outcome of extended-spectrum β-lactamase-producing enterobacter cloac...
16575005 - Treatment complications in children diagnosed with neuroblastoma during a screening pro...
24823955 - Choices for patients "without a choice": interviews with patients who received a left v...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-12-22
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  36     ISSN:  1365-2710     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-10-25     Completed Date:  2012-02-13     Revised Date:  2012-09-10    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  695-703     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. mtraperomarugan@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Female
Hepatitis C, Chronic / drug therapy*,  virology
Humans
Interferon-alpha / therapeutic use*
Male
Middle Aged
Polyethylene Glycols / therapeutic use*
Recombinant Proteins / therapeutic use
Retreatment
Ribavirin / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two...
Next Document:  Publishing bioethics and bioethics--reflections on academic publishing by a journal editor.